– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU – – Over $300 million of cash and investments on December 31, 2025, providing runway into Q4 2027 – WATERTOWN, Mass., March 04, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the fourth quarter and full-year ended December 31, 2025, and highlighted recent corporate developments. “Following a year of exceptional execution across our pivotal DURAVYU...

CALGARY, Alberta, March 04, 2026 (GLOBE NEWSWIRE) — Parex Resources Inc. (“Parex” or the “Company”) (TSX: PXT) is pleased to announce its financial and operating results for the three- and twelve-month periods ended December 31, 2025, as well as the results of its independent reserves assessment as at December 31, 2025. Additionally, the Company declares its Q1 2026 regular dividend of C$0.385 per share and provides an operational update. All amounts herein are in United States dollars (“USD”) unless otherwise stated. Key HighlightsGenerated annual funds flow provided by operations (“FFO”)(1) of $455 million and free funds flow(2) of $145 million in 2025. Increased both PDP and 1P reserves per share by 4% and 2P reserves per share by 8%, compared to 2024(3). Strong PDP, 1P, and 2P reserves replacement at 106%, 106%,...

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated Phase 1b dose finding study for CLR 125 in Triple Negative Breast Cancer with early data expected by mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., March 04, 2026 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2025, and provided a corporate update. “2025 was a productive year for Cellectar, marked by disciplined execution across our pipeline and meaningful clinical,...

LUXEMBOURG, March 04, 2026 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the fourth quarter and full year 2025. “We are pleased with our full year and fourth quarter 2025 performance driven by disciplined execution, reduced interest expense and strong sales wins. For the year, we grew Service revenue by $10.9 million, or 7%, to $161.3 million, Adjusted EBITDA(1) by $0.9 million, or 5%, to $18.3 million and significantly improved our GAAP loss before income taxes by $18.7 million to $14.1 million. The sales wins, including fourth quarter wins estimated to generate $13.2 million in stabilized annual revenue, should put us in a strong position to mitigate the...

Delivers Q4 net sales and earnings per share results above guidance Fourth quarter net sales of $2.7 billion, down 2%. Earnings per diluted share of $1.99; Adjusted earnings per diluted share of $2.05 Provides full-year 2026 guidance of net sales down 4.5% to down 2.5%, earnings per diluted share of $3.00 to $3.25; and adjusted earnings per diluted share of $2.40 to $2.65COLUMBUS, Ohio, March 04, 2026 (GLOBE NEWSWIRE) — Bath & Body Works, Inc. (NYSE: BBWI) today reported fourth quarter and full-year 2025 results. Daniel Heaf, chief executive officer of Bath & Body Works, commented, “Our fourth quarter results exceeded the guidance we provided. Since launching the Consumer First Formula in the third quarter, we have moved with urgency to accelerate innovation in our hero categories, refresh and modernize our brand,...

DASSAULT AVIATION RESULTSCONSOLIDATED DATA  2025 2024Order intake EUR 10,941 million 26 Export Rafale 31 Falcon EUR 10,869 million 30 Export Rafale 26 FalconAdjusted Net Sales(*) EUR 7,420 million 26 Rafaleof which 15 Export and 11 France 37 Falcon EUR 6,230 million 21 Rafale of which 14 France and 7 Export 31 FalconBacklog as of December 31 EUR 46,596 million 220 Rafale of which 175 Export and 45 France 73 Falcon EUR 43,224 million 220 Rafale of which 164 Export and 56 France 79 FalconAdjusted operating income(*) Adjusted operating margin EUR 635 million 8.6% of net sales EUR 519 million 8.3% of net salesSelf-funded Research and Development EUR 389 million 5.2% of net sales EUR 437 million 7.0% of net salesAdjusted net income(*) Adjusted net margin Earnings per share EUR 1,061 million 14.3% of net sales EUR 13.60...

With Harmony, Base44 and an ambitious roadmap ahead, Wix is reshaping how people create in the AI era and expanding the world of what’s possible onlineFinished 2025 with Q4 bookings of $535 million, up 15% y/y, and Q4 revenue of $524 million, up 14% y/y, driven by new cohort momentum and Base44 outperformance Base44 recently reached $100 million of ARR, powered by a fast-growing community of users building everything from simple apps to fully customized business software Healthy mid-teens top-line growth anticipated for 2026 as we drive forward ambitious product roadmaps, including Base44 and Wix HarmonyHarmony demonstrating strong early conversion and monetization, driving new core Wix cohort bookings growth acceleration in early 2026 Expect FCF1 margin in the low- to mid-20% range in 2026, reflecting the necessary investments to...

Press release4 March 2026 – N° 04   Fourth quarter 2025 results                 EUR 208 million net income in Q4 2025,contributing to a strong full year net income of EUR 851 million Proposed regular dividend of EUR 1.9 per shareGroup net income of EUR 208 million in Q4 2025 driven by all business activities (EUR 214 million adjusted1):P&C combined ratio of 80.9% with excellent attritional loss performance, allowing for buffer building L&H insurance service result2 of EUR 115 million, with an experience variance in line with expectations over the course of 2025 Investments regular income yield of 3.8%, with continued attractive reinvestment ratesQ4 annualized Return on Equity of 20.4% (21.1% adjusted1), implying full year 2025 Return on Equity of 19.2% (19.1% adjusted1) IFRS 17 Group Economic Value3 of EUR 8.5...

Achieved Average Working Interest Fourth Quarter Production of 46,344 BOEPD Realized 2025 Adjusted EBITDA1 of $284 Million Delivered Net Cash Provided by Operating Activities of $313 Million, up 31% from 2024 Generated 2025 Funds Flow from Operations1 of $178 Million Seventh Consecutive Year of South American Reserves Growth With Over 100% Reserve Replacement PDP & 2P Achieved Company’s Best Safety Performance on Record in 2025 Subsequent to Year-End Completed a Bond Exchange, Sold Non-Core Assets and Signed an Agreement in AzerbaijanCALGARY, Alberta, March 03, 2026 (GLOBE NEWSWIRE) — Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE) (TSX:GTE) (LSE:GTE) today announced the Company’s financial and operating results for the fourth quarter (“the Quarter”) and year ended December 31, 2025. Gran Tierra’s...

WARRENVILLE, Ill., March 03, 2026 (GLOBE NEWSWIRE) — Fuel Tech, Inc. (NASDAQ: FTEK), a technology company using advanced engineering processes to provide emissions control systems and water treatment technologies in utility and industrial applications, today reported financial results for the fourth quarter and full year ended December 31, 2025. “2025 was a year of achievement for Fuel Tech, highlighted by a resurgence at our FUEL CHEM® operations that produced the highest annual segment revenue since 2018, a broadened opportunity landscape at our Air Pollution Control (“APC”) business segment driven in large part by the expected growth of power generation to support data center construction and operation, and measurable progress at our Dissolved Gas Infusion (“DGI”) business segment,” said Vincent J. Arnone, President and CEO....